Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome

Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome

Bibliographic Details
Main Authors:	Christina Deligianni, Paolo Martelletti, Dimos D Mitsikostas
Format:	Article
Language:	English
Published:	Becaris Publishing Limited 2023-06-01
Series:	Journal of Comparative Effectiveness Research
Subjects:	bayesian network meta-analysis cgrp(r) monoclonal antibodies eptinezumab erenumab fremanezumab galcanezumab migraine network meta-regression prevention unanchored simulated treatment comparison

Similar Items

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
by: Theodoros Mavridis, et al.
Published: (2021-07-01)

Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence
by: Abubker Omaer, et al.
Published: (2024-04-01)

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
by: Antun R. Pavelic, et al.
Published: (2022-12-01)

Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
by: Suruchi Aditya, et al.
Published: (2023-01-01)

Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review
by: Theodoros Mavridis, et al.
Published: (2019-01-01)

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01)

Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
by: Licia Grazzi, et al.
Published: (2024-02-01)

A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?
by: Sena Uzun, et al.
Published: (2023-05-01)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
by: Larry Charleston, et al.
Published: (2023-08-01)

Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study
by: Abouch V. Krymchantowski, et al.
Published: (2023-03-01)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
by: Edoardo Caronna, et al.
Published: (2021-10-01)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
by: Simona Sacco, et al.
Published: (2019-01-01)

Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal
by: Yan Tereshko, et al.
Published: (2023-11-01)

Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
by: Taoufik Alsaadi, et al.
Published: (2024-02-01)

Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
by: Magdalena Nowaczewska, et al.
Published: (2022-05-01)

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety
by: M. T. Corasaniti, et al.
Published: (2023-12-01)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
by: Jessica Ailani, et al.
Published: (2022-06-01)

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
by: Timothy R. Smith, et al.
Published: (2021-11-01)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
by: Panagiotis Gklinos, et al.
Published: (2021-03-01)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
by: Hugo Sevivas, et al.
Published: (2022-06-01)

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody
by: Larisa A. Dobrynina, et al.
Published: (2023-06-01)

A prospective real-world analysis of erenumab in refractory chronic migraine
by: Giorgio Lambru, et al.
Published: (2020-06-01)

Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience
by: Marcello Silvestro, et al.
Published: (2022-06-01)

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
by: Angelo Camporeale, et al.
Published: (2018-11-01)

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
by: Peter McAllister, et al.
Published: (2022-02-01)

Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis
by: Anna P. Andreou, et al.
Published: (2022-11-01)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-10-01)

Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry
by: Victor Obach, et al.
Published: (2023-11-01)

A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB
by: Giuseppe Tringali, et al.
Published: (2020-10-01)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
by: Mark E. Bangs, et al.
Published: (2020-01-01)

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments
by: Dulanji K. Kuruppu, et al.
Published: (2021-04-01)

A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine
by: Saval Khanal, et al.
Published: (2022-09-01)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
by: Agaath Hedina Manickam, et al.
Published: (2021-08-01)

Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
by: Roger Cady, et al.
Published: (2022-07-01)

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
by: Andrew Blumenfeld, et al.
Published: (2022-07-01)

Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study
by: Keiko Ihara, et al.
Published: (2023-03-01)

Erenumab efficacy predictors for chronic migraine
by: Nina V. Vashchenko
Published: (2022-02-01)

Photophobia and migraine outcome during treatment with galcanezumab
by: Francesca Schiano di Cola, et al.
Published: (2023-01-01)

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study
by: Yazan Bader, et al.
Published: (2023-07-01)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
by: Piero Barbanti, et al.
Published: (2022-04-01)